Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis
1. In this randomized trial, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete ...
Tag: Obinutuzumab
#VisualAbstract: Obinutuzumab Plus Standard Therapy Provided Complete Renal Response in Active Lupus Nephritis
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence ...
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence ...
#Visual Abstract: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared ...
The CLL14 trial: longer progression-free survival for CLL patients with coexisting conditions treated with venetoclax
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared ...